Literature DB >> 28616844

Therapeutic Utility of Opioids for Restless Legs Syndrome.

Susan E Mackie1, John W Winkelman2.   

Abstract

Restless legs syndrome (RLS) is a sensorimotor neurologic disorder characterized by an unpleasant urge to move the legs, often accompanied by leg dysesthesias. Symptoms predominate in the evening or at night and often cause significant distress and disruption of sleep. Several non-opioid classes of drugs provide initial relief from the symptoms of RLS. Among these, however, the efficacy of dopamine agonists can wane over time or even paradoxically 'augment' the severity of symptoms during the course of long-term treatment. Opioids can alleviate RLS symptoms, even in patients who have become refractory to, or do not tolerate, other drugs. In a carefully selected group of patients with severe RLS that has not been effectively managed with other therapies, opioids may be an appropriate treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28616844     DOI: 10.1007/s40265-017-0773-6

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  46 in total

1.  Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease).

Authors:  D Tzonova; O Larrosa; E Calvo; J J Granizo; A-M Williams; Y de la Llave; D García-Borreguero
Journal:  Sleep Med       Date:  2012-01-26       Impact factor: 3.492

2.  The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG).

Authors:  Marco Zucconi; Raffaele Ferri; Richard Allen; Paul Christian Baier; Oliviero Bruni; Sudhansu Chokroverty; Luigi Ferini-Strambi; Stephany Fulda; Diego Garcia-Borreguero; Wayne A Hening; Max Hirshkowitz; Birgit Högl; Magdolna Hornyak; Martin King; Pasquale Montagna; Liborio Parrino; Giuseppe Plazzi; Mario G Terzano
Journal:  Sleep Med       Date:  2006-02-03       Impact factor: 3.492

3.  Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance.

Authors:  Richard P Allen; Daniel L Picchietti; Diego Garcia-Borreguero; William G Ondo; Arthur S Walters; John W Winkelman; Marco Zucconi; Raffaele Ferri; Claudia Trenkwalder; Hochang B Lee
Journal:  Sleep Med       Date:  2014-05-17       Impact factor: 3.492

Review 4.  The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Nisha Aurora; David A Kristo; Sabin R Bista; James A Rowley; Rochelle S Zak; Kenneth R Casey; Carin I Lamm; Sharon L Tracy; Richard S Rosenberg
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

5.  Epidemiology of restless legs symptoms in adults.

Authors:  B Phillips; T Young; L Finn; K Asher; W A Hening; C Purvis
Journal:  Arch Intern Med       Date:  2000-07-24

6.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

Review 7.  The Role of Periodic Limb Movements During Sleep in Restless Legs Syndrome: A Selective Update.

Authors:  Stephany Fulda
Journal:  Sleep Med Clin       Date:  2015-06-22

8.  Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.

Authors:  Diego García-Borreguero; Richard P Allen; Ralf Kohnen; Birgit Högl; Claudia Trenkwalder; Wolfgang Oertel; Wayne A Hening; Walter Paulus; David Rye; Arthur Walters; Juliane Winkelmann; Christopher J Earley
Journal:  Sleep Med       Date:  2007-06-01       Impact factor: 3.492

9.  The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study.

Authors:  Sarah von Spiczak; Alan L Whone; Alexander Hammers; Marie-Claude Asselin; Federico Turkheimer; Tobias Tings; Svenja Happe; Walter Paulus; Claudia Trenkwalder; David J Brooks
Journal:  Brain       Date:  2005-02-23       Impact factor: 13.501

Review 10.  Long-term opioid management for chronic noncancer pain.

Authors:  Meredith Noble; Jonathan R Treadwell; Stephen J Tregear; Vivian H Coates; Philip J Wiffen; Clarisse Akafomo; Karen M Schoelles
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more
  2 in total

1.  Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Authors:  Ning-Sheng Cai; César Quiroz; Jordi Bonaventura; Alessandro Bonifazi; Thomas O Cole; Julia Purks; Amy S Billing; Ebonie Massey; Michael Wagner; Eric D Wish; Xavier Guitart; William Rea; Sherry Lam; Estefanía Moreno; Verònica Casadó-Anguera; Aaron D Greenblatt; Arthur E Jacobson; Kenner C Rice; Vicent Casadó; Amy H Newman; John W Winkelman; Michael Michaelides; Eric Weintraub; Nora D Volkow; Annabelle M Belcher; Sergi Ferré
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

2.  Preface for the 3rd Clinical Update Sleep, 23rd February 2018, Royal College of Physicians, London, UK: year in review.

Authors:  Culadeeban Ratneswaran; Manpreet K Sagoo; Joerg Steier
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.